1800-272-662
Shopping Cart 0
countryflagAU
Login

Immatics NV

Healthcare US IMTX

9.24USD
-0.17(1.81%)

Last update at 2026-03-13T20:09:00Z

Day Range

9.139.83
LowHigh

52 Week Range

7.1513.16
LowHigh

Fundamentals

  • Previous Close 9.41
  • Market Cap1202.63M
  • Volume255614
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-98.35200M
  • Revenue TTM54.00M
  • Revenue Per Share TTM0.67
  • Gross Profit TTM 172.83M
  • Diluted EPS TTM-1.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 42.04M -93.33500M -229.61600M -32.48700M -32.35500M
Minority interest 0.00000M 0.00000M 0.56M 1.02M 1.24M
Net income 37.51M -95.06100M -229.34800M -31.74100M -31.44400M
Selling general administrative 36.12M 33.81M 34.19M 11.76M 7.67M
Selling and marketing expenses - - - - -
Gross profit 172.83M 34.76M 31.25M 18.45M 3.77M
Reconciled depreciation 6.97M 5.26M 4.42M 3.86M 2.18M
Ebit 29.95M -86.29400M -69.71500M -33.01300M -33.90200M
Ebitda 46.34M -75.35900M -64.44100M -28.36500M -31.72600M
Depreciation and amortization 16.38M 10.94M 5.27M 4.65M 2.18M
Non operating income net other - - - - -
Operating income 29.95M -86.29400M -69.71500M -33.01300M -34.40900M
Other operating expenses 142.88M 121.05M 100.97M 51.46M 38.18M
Interest expense 8.28M 1.73M 0.29M 0.17M 0.02M
Tax provision 4.52M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 2.48M 5.67M 0.85M 3.35M 0.74M
Net interest income 1.44M 3.95M 0.56M 0.62M 0.49M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 4.55M 1.73M -0.26800M -0.74600M -2.96500M
Total revenue 172.83M 34.76M 31.25M 18.45M 3.77M
Total operating expenses 142.88M 121.05M 100.97M 51.46M 38.18M
Cost of revenue - - - - -
Total other income expense net 12.08M -7.04100M -159.90100M 0.53M 1.56M
Discontinued operations - - - - -
Net income from continuing ops 37.51M -93.33500M -229.61600M -32.48700M -32.35500M
Net income applicable to common shares 37.51M -93.33500M -211.28400M -31.57100M -31.44400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 509.96M 407.82M 174.65M 254.65M 134.28M
Intangible assets 1.52M 1.63M 1.31M 0.91M 1.01M
Earning assets - - - - -
Other current assets 7.12M 13.84M 6.41M 0.79M 0.67M
Total liab 284.88M 194.66M 150.58M 150.39M 175.11M
Total stockholder equity 225.08M 213.16M 24.06M 104.26M -41.85500M
Deferred long term liab - - - - -
Other current liab 45.88M 26.28M 30.41M 9.57M 3.39M
Common stock 0.85M 0.77M 0.63M 0.63M 1.16M
Capital stock 0.85M 0.77M 0.63M 0.63M 1.16M
Retained earnings -597.29300M -500.29900M -537.81300M -462.25300M -233.19400M
Other liab - - 48.29M 85.47M 103.99M
Good will - - - - -
Other assets - 2.54M 0.64M 0.72M 1.26M
Cash 218.47M 148.52M 132.99M 207.53M 103.35M
Cash and equivalents - - - - -
Total current liabilities 156.55M 106.45M 95.15M 60.61M 69.30M
Current deferred revenue 100.40M 64.96M 50.40M 46.60M 59.63M
Net debt -203.07000M -133.95700M -123.14100M -201.34300M -100.11900M
Short term debt 2.60M 2.16M 2.71M 1.88M 1.41M
Short long term debt - - - - -
Short long term debt total 15.40M 14.56M 9.85M 6.19M 3.23M
Other stockholder equity 823.17M 714.18M 565.19M 573.34M 190.94M
Property plant equipment - 26.49M 20.49M 14.02M 8.01M
Total current assets 449.37M 377.15M 152.21M 238.99M 124.00M
Long term investments - - - - -
Net tangible assets - 211.53M 22.75M 86.47M -42.86300M
Short term investments 207.42M 213.69M 12.12M 24.45M 16.02M
Net receivables 5.74M 1.11M 0.68M 2.92M 2.72M
Long term debt - - - - -
Inventory 10.62M - - 3.30M 1.24M
Accounts payable 7.67M 13.06M 11.62M 2.55M 4.87M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.63600M -1.48100M -3.94500M -7.45900M -0.77000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.02M 2.54M 0.64M 0.73M 1.26M
Deferred long term asset charges - - - - -
Non current assets total 60.59M 30.67M 22.44M 15.65M 10.28M
Capital lease obligations 15.40M 14.56M 9.85M 6.19M 3.23M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -209.79100M 13.15M -8.42500M -2.92200M -13.10100M
Change to liabilities 45.56M -31.78400M -23.38700M 98.94M 43.73M
Total cashflows from investing activities -209.79100M 7.49M -15.94900M -5.05900M -13.51400M
Net borrowings -2.84300M -2.70700M -2.09600M -1.86200M -1.86200M
Total cash from financing activities 123.71M -2.61300M 207.88M -1.86200M 23.65M
Change to operating activities -7.87200M -0.48300M -1.60000M -1.49700M 5.61M
Net income 37.51M -93.33500M -229.61600M -32.48700M -32.35500M
Change in cash 15.53M -74.53600M 104.18M 63.99M 30.95M
Begin period cash flow 132.99M 207.53M 103.35M 39.37M 8.41M
End period cash flow 148.52M 132.99M 207.53M 103.35M 39.37M
Total cash from operating activities 100.13M -81.78400M -85.61000M 70.97M 20.68M
Issuance of capital stock 134.48M 0.09M 217.92M 0.00000M 23.65M
Depreciation 6.97M 5.26M 4.42M 3.86M 2.18M
Other cashflows from investing activities - - - - -143.75000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.42900M 0.57M -0.29400M -0.56300M -0.17500M
Sale purchase of stock - - - - 149.70M
Other cashflows from financing activities -7.93100M 7.49M -7.93900M -5.05900M -13.51400M
Change to netincome 18.39M 37.99M -6.25600M 1.80M 0.79M
Capital expenditures 6.21M 5.66M 7.52M 2.23M 0.51M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 37.26M -31.69800M -25.28100M 96.88M 49.16M
Stock based compensation 22.57M 26.40M 22.95M 0.85M 1.48M
Other non cash items -8.70000M 0.43M 145.87M 1.24M -0.27100M
Free cash flow 93.92M -87.44100M -93.13400M 68.73M 20.18M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IMTX
Immatics NV		 -0.17 1.81% 9.24 - - 20.24 4.51 12.06 -7.3242
NVO
Novo Nordisk A/S		 -0.06 0.16% 37.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.315 0.82% 38.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -8.79 1.84% 469.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -0.84 0.11% 745.77 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Immatics NV

Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076

Key Executives

Name Title Year Born
Dr. Harpreet Singh Ph.D. CEO, MD, Member of Management Board & Supervisory Director 1975
Dr. Hans-Georg Rammensee Ph.D. Co-Founder & Member of the Scientific Advisory Board NA
Dr. Toni Weinschenk Ph.D. Co-Founder & Chief Innovation Officer 1973
Mr. Arnd Christ MBA Chief Financial Officer 1966
Mr. Steffen Walter Ph.D. Chief Technology Officer 1976
Mr. Edward A. Sturchio Gen. Counsel & Sec. NA
Ms. Anja Heuer B.Sc. Director of Corp. Communications NA
Ms. Tamara Louw M.B.A., P.H.R. Sr. Director of HR NA
Dr. Carsten Reinhardt M.D., Ph.D. Chief Devel. Officer 1967
Dr. Rainer Kramer Ph.D. Chief Bus. Officer & Site Head Munich 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.